Answers are grounded in this paper and cite their sources.
Background Anti–tumor necrosis factor-alpha (anti-TNF) agents are recommended as third-line therapy in refractory pulmonary sarcoidosis. Neurological adverse events, including peripheral neuropathy, are rare and typically occur months after treatment initiation.Case presentation We describe a 30-year-old man with long-standing pulmonary and ocular sarcoidosis who developed rapidly progressive peripheral neuropathy shortly after initiation of adalimumab. The patient had been treated for several years with glucocorticoids, methotrexate, and infliximab, but was switched to adalimumab due to high titers of anti-infliximab antibodies and refractory ocular disease. After two subcutaneous injections of adalimumab (40 mg biweekly), he developed sensory symptoms in all extremities, progressing within days to painful hypersensitive neuropathy and distal motor weakness. Electrophysiological studies demonstrated an axonal sensorimotor neuropathy. Cerebrospinal fluid analysis showed inflammatory changes with elevated protein levels, while MRI of the central nervous system was normal. Adalimumab was discontinued, and treatment with high-dose glucocorticoids and gabapentin resulted in partial clinical improvement.Conclusion Rapid-onset axonal peripheral neuropathy following adalimumab is rare, particularly in sarcoidosis. This case underscores the importance of early recognition and discontinuation of anti-TNF therapy.
No takes yet. Share an insight, caveat, or question.
Ullmann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: